Last reviewed · How we verify

Cefazolin / Vancomycin — Competitive Intelligence Brief

Cefazolin / Vancomycin (Cefazolin / Vancomycin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic / Glycopeptide antibiotic. Area: Infectious Disease.

marketed Beta-lactam antibiotic / Glycopeptide antibiotic Penicillin-binding proteins / D-Ala-D-Ala peptidoglycan precursors Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Cefazolin / Vancomycin (Cefazolin / Vancomycin) — University of Cincinnati. Cefazolin and vancomycin are bactericidal antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and D-Ala-D-Ala residues, respectively.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cefazolin / Vancomycin TARGET Cefazolin / Vancomycin University of Cincinnati marketed Beta-lactam antibiotic / Glycopeptide antibiotic Penicillin-binding proteins / D-Ala-D-Ala peptidoglycan precursors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic / Glycopeptide antibiotic class)

  1. University of Cincinnati · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cefazolin / Vancomycin — Competitive Intelligence Brief. https://druglandscape.com/ci/cefazolin-vancomycin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: